By Jared Chausow
By Katie Toth
By Elizabeth Flock
By Albert Samaha
By Anna Merlan
By Jon Campbell
By Jon Campbell
By Albert Samaha
But the story bombed in the medical community. Three catch-up stories, two Times editorials, a full-page protest ad, one op-ed, one Week in Review piece, and one Jane Brody column later, the Times has lavished attention on Kolata's original thesis, maintaining the hype while cushioning the news with qualifiers. In a long news story on February 11, the Times covered its ass by restating the pre-Kolata consensus: Women over 40 should get regular mammograms, because the benefits outweigh the risks.
To be sure, cancer screening and treatment are sometimes more aggressive than breast cancer itself. And as Barbara Ehrenreich recently wrote in Harper's, there is too much happy talk about cures. But as a recent Times op-ed put it, "Regular Mammograms Remain a Crucial Tool."
The revisions came quickly, but the damage had already been done. In the wake of Kolata's January 24 story, women begged experts for advice, senators scheduled hearings, and TV and print reporters scrambled to clean up the mess. Journalists say that in private, some doctors wondered why the Times issued a call for revised guidelines before the profession reached a consensus, and others said the Times had given women an excuse not to get mammograms.
Few would criticize the Times publicly. But the diagnosis is grim. Rather than clarifying a public health issue, Kolata has created mass confusion by turning mammography into a yes-or-no proposition. Kolata feigns objectivity, but not everyone has forgotten an October 1998 Brill's Content story that blasted her for a series of overhyped, one-sided, pro-business vendettas.
"Gina Kolata has a reputation for not being afraid to drive a story," said a reporter who has been covering science for several years and whose company competes with the Times. "She doesn't sit back and try real hard to be fair." The diciest part of Kolata's latest thesis is that "she acts as though it's common knowledge that everybody agrees early detection of breast cancer may not be the best thing." Plus, the studies Kolata pounced on were not news. "She makes breathtaking comments and puts a spin on it, and they put it on page one!"
As Kolata repeatedly told Brill's Content, "I have no agenda."
But Times big shots know that when they say, Jump, the medical establishment says, How high? And so Kolata's thesis was transported out of the news hole into the agenda-setting opinion pages. An editorial on January 27 championed the mammogram skeptics and demanded that the National Cancer Institute fall in line.
The reaction was obviously not what the Times expected. On January 31, 10 groups including the American Cancer Society and American Medical Association took out a full-page ad in the Times, titled "An Open Letter to Women and Their Physicians." The ad did not mention the Times, but the message could not have been clearer: Contrary to recent "coverage in the media and the resulting . . . discussion," the ad said, mammograms are effective and a lifesaver.
Again, the response was swift. In a February 5 piece by Kolata, the Times made a show of fairness, even running head shots of experts on both sides. But the next day, a Times editorial accused the cancer establishment of circling the wagons and hanging on to a profitable status quo.
Meanwhile, Kolata continued giving the best play to Dr. Donald Berry, the skeptic whose views shaped her original story. On February 5, she reported that Berry is conducting a study to establish whether mammograms or cancer drugs are most responsible for declining mortality rates.
So what's Berry's agenda? In addition to running the biostatistics department at the M.D. Anderson Cancer Center in Houston, he chairs the National Cancer Institute panel whose findings Kolata reported as front-page news. In an interview with the Voice, Berry said the panel maintains a Web site for the NCI, but does not determine NCI policy.
Berry described his motives as "noble," in the best interests of women at risk, adding, "What possibly could be in it for me?" Asked if he had relevant financial ties, he said, "I do consulting for drug companies, but none of them are relevant," because manufacturers of cancer drugs would not benefit from less use of mammography.
According to his résumé, Berry began consulting for Bristol-Myers Squibb (BMS) in 1998. BMS makes Taxol, a drug used with chemotherapy as a treatment for ovarian cancer and advanced breast cancer. According to a January 2000 article in Texas Monthly, Berry participated in a study of Taxol as a possible treatment for primary breast cancer, and helped BMS with an FDA application that would allow Taxol to be marketed for that purpose.
In subsequent e-mails, Berry said it was "ridiculous" to connect his views on mammography with his work for a pharmaceutical company, pointing out that his criticisms of mammography trials had already been published "in 1998, before I consulted for BMS."